Quarterly ResultAug 3, 2026, 04:08 PM
Keros Therapeutics Q2 Revenue $0; Net Loss $28.7M
AI Summary
Keros Therapeutics reported a net loss of $28.71 million for the second quarter of 2026, with total revenue at $0, a significant decrease from the prior year's period which included license revenue. For the first six months of 2026, the company posted a net loss of $52.42 million, contrasting with a net income of $117.76 million in the same period of 2025. Cash and cash equivalents stood at $257.61 million as of June 30, 2026, reflecting ongoing operational expenses for its clinical-stage pipeline.
Key Highlights
- Q2 2026 total revenue was $0, down from $18.17 million in Q2 2025.
- Q2 2026 net loss was $28.71 million, compared to a net loss of $30.70 million in Q2 2025.
- H1 2026 net loss was $52.42 million, compared to net income of $117.76 million in H1 2025.
- Cash and cash equivalents totaled $257.61 million as of June 30, 2026.
- Net cash used in operating activities was $23.95 million for H1 2026.
- R&D expenses decreased to $22.33 million in Q2 2026 from $43.50 million in Q2 2025.
- Completed $375 million capital return program (buyback) in Q4 2025.
Price Impact
More from KROS